{"title":"Expression of serum HMGB1, SAA, and TSGF in patients with colon cancer and the value of prognostic assessment.","authors":"Kaifeng Wang, Junxing Huang","doi":"10.1177/18758592241297848","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To investigate the expression of serum high mobility group protein 1 (HMGB1), amyloid A (SAA), and tumor-specific growth factor (TSGF) in patients with colon cancer (CRC) and the value of prognostic assessment. <b>Methods:</b> Sixty cases of CRC patients admitted to our hospital from January 2018 to December 2020 were selected and set as the CRC group; 60 cases of inflammatory bowel disease (IBD) patients admitted during the same period were set as the IBD group, and 60 cases of those who were admitted to the hospital for health experience during the same period were set as the control group. The serum HMGB1, SAA, and TSGF levels of each group were detected to analyze their expression in CRC patients and their relationship with prognosis, compare the serum HMGB1, SAA, and TSGF levels of each group, and compare the serum HMGB1, SAA, and TSGF levels of patients with CRC with different clinical features. After 8 to 36 months of follow-up, CRC patients were grouped according to their prognosis (good prognosis group and poor prognosis group), and serum HMGB1, SAA, and TSGF levels were compared between the two groups. The predictive value of serum HMGB1, SAA, TSGF and their combined assays on the prognosis of CRC patients was analyzed using the subject's work characteristic curve (ROC). <b>Results:</b> Serum HMGB1, SAA, and TSGF levels were significantly higher in the CRC group than in the IBD group (<i>P </i>< 0.05), and serum HMGB1, SAA, and TSGF levels were significantly higher in the IBD group than in the control group (<i>P </i>< 0.05). Serum HMGB1, SAA, and TSGF levels were significantly higher in the CRC group than in the patients with TNM staging III than in the patients with TNM staging I-II (<i>P </i>< 0.05). Serum HMGB1, SAA, and TSGF levels were significantly higher in patients with low differentiation than in patients with middle and high differentiation (<i>P </i>< 0.05), serum HMGB1, SAA, and TSGF levels were significantly higher in patients with low differentiation than in patients with intermediate and high differentiation (<i>P </i>< 0.05), and serum HMGB1, SAA, and TSGF levels were significantly higher in those who developed lymph node metastasis than in patients with intermediate and high differentiation (<i>P </i>< 0.05). Serum HMGB1, SAA, and TSGF levels in the poor prognosis group were significantly higher than those of patients in the good prognosis group (<i>P </i>< 0.05). The ROC curves showed that the area under the curve (AUC) of serum HMGB1, SAA, and TSGF for predicting the prognosis of patients with CRC were 0.790, 0.774, 0.733, respectively, and that the combined assay predicted the prognosis of patients with CRC with an AUC of 0903, which was higher than that of the test alone (<i>Z </i>= 2.536, 2.420, 2.218, <i>P </i>= 0.013, 0.020, 0.031). <b>Conclusion:</b> Serum HMGB1, SAA, and TSGF expression was significantly higher in colon cancer patients than in patients with inflammatory bowel disease and healthy populations, and was associated with TNM stage, degree of differentiation, and the presence of lymph node metastasis.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 6","pages":"18758592241297848"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biomarkers : section A of Disease markers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/18758592241297848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the expression of serum high mobility group protein 1 (HMGB1), amyloid A (SAA), and tumor-specific growth factor (TSGF) in patients with colon cancer (CRC) and the value of prognostic assessment. Methods: Sixty cases of CRC patients admitted to our hospital from January 2018 to December 2020 were selected and set as the CRC group; 60 cases of inflammatory bowel disease (IBD) patients admitted during the same period were set as the IBD group, and 60 cases of those who were admitted to the hospital for health experience during the same period were set as the control group. The serum HMGB1, SAA, and TSGF levels of each group were detected to analyze their expression in CRC patients and their relationship with prognosis, compare the serum HMGB1, SAA, and TSGF levels of each group, and compare the serum HMGB1, SAA, and TSGF levels of patients with CRC with different clinical features. After 8 to 36 months of follow-up, CRC patients were grouped according to their prognosis (good prognosis group and poor prognosis group), and serum HMGB1, SAA, and TSGF levels were compared between the two groups. The predictive value of serum HMGB1, SAA, TSGF and their combined assays on the prognosis of CRC patients was analyzed using the subject's work characteristic curve (ROC). Results: Serum HMGB1, SAA, and TSGF levels were significantly higher in the CRC group than in the IBD group (P < 0.05), and serum HMGB1, SAA, and TSGF levels were significantly higher in the IBD group than in the control group (P < 0.05). Serum HMGB1, SAA, and TSGF levels were significantly higher in the CRC group than in the patients with TNM staging III than in the patients with TNM staging I-II (P < 0.05). Serum HMGB1, SAA, and TSGF levels were significantly higher in patients with low differentiation than in patients with middle and high differentiation (P < 0.05), serum HMGB1, SAA, and TSGF levels were significantly higher in patients with low differentiation than in patients with intermediate and high differentiation (P < 0.05), and serum HMGB1, SAA, and TSGF levels were significantly higher in those who developed lymph node metastasis than in patients with intermediate and high differentiation (P < 0.05). Serum HMGB1, SAA, and TSGF levels in the poor prognosis group were significantly higher than those of patients in the good prognosis group (P < 0.05). The ROC curves showed that the area under the curve (AUC) of serum HMGB1, SAA, and TSGF for predicting the prognosis of patients with CRC were 0.790, 0.774, 0.733, respectively, and that the combined assay predicted the prognosis of patients with CRC with an AUC of 0903, which was higher than that of the test alone (Z = 2.536, 2.420, 2.218, P = 0.013, 0.020, 0.031). Conclusion: Serum HMGB1, SAA, and TSGF expression was significantly higher in colon cancer patients than in patients with inflammatory bowel disease and healthy populations, and was associated with TNM stage, degree of differentiation, and the presence of lymph node metastasis.
目的:探讨结肠癌(CRC)患者血清高迁移率组蛋白1 (HMGB1)、淀粉样蛋白A (SAA)、肿瘤特异性生长因子(TSGF)的表达及其对预后的评价价值。方法:选取2018年1月至2020年12月我院收治的60例结直肠癌患者作为结直肠癌组;选取同期入院的炎症性肠病(IBD)患者60例作为IBD组,选取同期入院进行健康体验的患者60例作为对照组。检测各组患者血清HMGB1、SAA、TSGF水平,分析其在结直肠癌患者中的表达及其与预后的关系,比较各组患者血清HMGB1、SAA、TSGF水平,比较不同临床特征结直肠癌患者血清HMGB1、SAA、TSGF水平。随访8 ~ 36个月后,根据CRC患者预后情况进行分组(预后好组和预后差组),比较两组患者血清HMGB1、SAA、TSGF水平。采用受试者工作特征曲线(ROC)分析血清HMGB1、SAA、TSGF及其联合检测对结直肠癌患者预后的预测价值。结果:CRC组血清HMGB1、SAA、TSGF水平显著高于IBD组(P P P P P P P Z = 2.536、2.420、2.218,P = 0.013、0.020、0.031)。结论:结肠癌患者血清HMGB1、SAA、TSGF表达水平明显高于炎性肠病患者和健康人群,且与TNM分期、分化程度、有无淋巴结转移有关。